FOXO4-DRI
FOXO4-DRI is a peptide, indexed here under Mitochondrial and longevity-associated peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Mitochondrial and longevity-associated peptides |
| CAS registry number | 2460055-10-9[1] |
| PubChem CID | 167312269[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C228H388N86O64[1] |
| Molecular weight | 5358 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
FOXO4-DRI is a D-retro-inverso peptide described in the retrieved literature as a senolytic. A 2025 Nature Communications paper reports that the disordered p53 transactivation domain is the target of FOXO4 and of the compound, and a 2025 Communications Biology paper reports apoptosis of keloid senescent fibroblasts through nuclear exclusion of phosphorylated p53.
The remaining records are cell and mouse models of senescence: a 2020 Aging paper on senescent Leydig cells and testosterone secretion in aged mice, a 2021 Frontiers in Bioengineering and Biotechnology paper on removal of senescent cells from expanded human chondrocytes, a 2023 Naunyn-Schmiedeberg’s Archives of Pharmacology paper on extracellular matrix production by fibroblasts in a bleomycin model of pulmonary fibrosis, a 2024 Experimental Gerontology paper on spermatogenesis in aged mice, and a 2025 Frontiers in Bioengineering and Biotechnology paper on endothelial cell senescence through p53 signalling.
[3, 4, 5, 6, 7, 8, 9]Reported mechanism
A senolytic peptide reported in the retrieved records to target the FOXO4 interaction with the p53 transactivation domain, releasing p53 in senescent cells.
[3, 4]Stated in the titles of the cited 2025 Nature Communications and 2025 Communications Biology papers.
Targets named in the cited records: FOXO4, p53.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
FOXO4-DRI appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- FOXO4 D-retro-inverso
- FOXO4-D-Retro-Inverso peptide
Where this page sits
Research records
Cited research records for FOXO4-DRI, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Epitalon — Mitochondrial and longevity-associated peptides
- Humanin — Mitochondrial and longevity-associated peptides
Class page: Mitochondrial and longevity-associated peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide described in the retrieved literature as a senolytic. A 2025 Nature Communications paper reports that the disordered p53 transactivation domain is the target of FOXO4 and of the compound, and a 2025 Communications Biology paper reports apoptosis of keloid senescent fibroblasts through nuclear exclusion of phosphorylated p53.
Which class is FOXO4-DRI indexed under?
FOXO4-DRI is indexed under Mitochondrial and longevity-associated peptides. This class groups peptides whose retrieved literature concerns mitochondrial function or ageing endpoints.
What does the FDA application register show for FOXO4-DRI?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 167312269, Foxo4-dri. PubChem, National Library of Medicine (2026). pubchem:167312269
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:foxo4-dri
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications (2025). pmid:40593617
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology (2025). pmid:39994346
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (2020). pmid:31959736
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From <i>in vitro</i> Expanded Human Chondrocytes. Frontiers in bioengineering and biotechnology (2021). pmid:33996787
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's archives of pharmacology (2023). pmid:37074394
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental gerontology (2024). pmid:39025385
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology (2025). pmid:41625068
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.